Have you ever been so tired that the moment you hit the bed, you feel like you are sinking in your mattress? Or did you ever feel your leg twitch in middle of your sleep? Did you feel like you moved your leg to prevent yourself from falling down? If yes, then you are in for a great read!
You are not alone, this happens to around 70% of the total population in some way or another. Although these are signs of sleep disorders, it can also happen to people who are otherwise healthy. Sleep disorder specialists believe that there are certain common triggers that leads to such a sensation.
Our brain is exceptional and sometimes when we dream, it makes us believe that we our part of the dream. And if you are falling from somewhere in your dream, chances are, you would feel like you are falling in real life. This experience is known as hypnic jerk, the movement of your muscle that helps you be safe from that fall, or the imaginary one.
What causes it? When we sleep, our bodies become paralyzed, but that does not mean that our muscle control is not totally off. Rather, a slow, dimmer switch. When the dim switch randomly is turned on, we get jerky movements in our sleep.
This involuntary muscle movement is also called myoclonus or hypnic myoclonus, that transitions as you shift from one sleep phase into another.
ALSO SEE: What is sleep paralysis?
There are many theories on what might be causing it. One of them is that when you are at this stage of sleep, you are still not in deep sleep and your brain misinterprets it as wakefulness, however, at the same time your brain does not recognize your muscles to be moving. This is what leads your brain to send a message to your muscles to check-in. It is a way your brain tries to protect you.
Another theory is of course that of stress. When you are stressed, your mind might be racing, while your body is in stationary. This can also affect your sleep cycle and your sleep can be disrupted.
If you are on stimulant drugs or alcohol, it too can prevent you from achieving a good night sleep. If you have consumed too much caffeine then too your muscles can twitch to make you stay awake.
Furthermore, lack of sleep could also be the reason why your mind is used to staying awake even if your body really needs the rest.
While the falling sensation in sleep is quite common, and happens to healthy people, a severe form is the Periodic Limb Movement Disorder (PLMD). PLMD is a repetitive cramping or jerking of legs during sleep. It is a movement disorder that happens only during sleep. It is called "periodic" because the movements are repetitive and rhythmic, which means it occurs in every 20 to 40 seconds. It is also often linked with restless legs syndrome, however, the two are not the same thing.
Restless leg syndrome on the other hand is a condition that involves strange sensations in the legs and arms while awake and an irresistible urge to move the limbs to relive the sensations.
What causes PLMD may be more severe things, including diabetes, iron deficiency, spinal cord tumor, spinal cord injury, sleep apnea, uremia, anemia, narcolepsy, or certain medications.
Credit: AI
A surgeon, sitting hundreds of kilometres away, can now operate on a patient undergoing complex procedure by controlling a robotic system. This is no longer just an inexplicable futuristic idea.
India has already seen a major development in robotic telesurgery, as doctors explore whether advanced surgical systems can help connect specialist surgeons with patients in different cities where such expertise may not be accessible.
According to data presented at the Society of Robotic Surgery (SRS) India 2026 conference in New Delhi, the development comes as robotic surgery itself is expanding rapidly across India. Delhi NCR has emerged as the country's leading hub for robotic surgery.
Addressing the SRS India 2026 Conference virtually, Union Minister for Health and Family Welfare Shri J.P. Nadda said "Today India stands at an exciting juncture in the healthcare innovation, with our strength in technology, Artificial Intelligence, digital health and a rapidly expanding ecosystem of surgical robotics, we have opportunity, not nearly to adopt the technology of the future but innovate ,develop and lead. India is increasingly becoming an important global destination for healthcare innovation and advance surgical technology. I congratulate organizers for bringing this important international conference to India."
According to the conference data, 39 hospitals in Delhi NCR now have robotic systems, while 11 hospitals have more than one system. The number of robotic-assisted procedures in the region has also increased from 2,257 in 2021 to 10,937 in 2025. Across India, the growth in robotic surgical procedures increased from 8,912 in 2021 to 44,857 in 2025.
Urology accounted for about 30.2% of robotic procedures in Delhi NCR in 2025, while general surgery-benign procedures made up around 33% and gynaecology 22.1%.
Dr. Vivek Bindal, Organising Chairman, SRS India and Principal Director & Head, Department of Minimal Access, Bariatric & Robotic Surgery, Max Hospital, New Delhi, said, “Delhi NCR has emerged as a leading force in India’s robotic surgery journey, with the highest concentration of robotic-system installations in the country and a rapidly expanding volume of procedures. The presence of robotic systems across 39 hospitals, including 11 hospitals with multiple systems, reflects the depth of expertise and institutional adoption that has developed in the region."
He added, "Delhi has reached this position because of the combined efforts of pioneering surgeons, high-volume hospitals and multidisciplinary teams that have steadily integrated robotic technology into complex surgical care. What we are witnessing is not simply an increase in machines or procedures, but the emergence of Delhi as a centre that is helping shape the future of robotic surgery in India."
Prof. Dr. Anup Kumar, Professor & Head, Department of Urology, Robotics & Renal Transplant, VMMC & Safdarjung Hospital, New Delhi, recently performed India's first government-institution robotic telesurgery in urology.
The reconstructive procedure was performed remotely from Gurugram to Preeti Kidney & Urology Hospital in Hyderabad.
The accomplishment has raised the possibility of specialist surgeons operating on patients who are located in smaller cities with limited resources and access.
Also read: 22-Year-Old Woman Undergoes Robotic Heart Surgery After Two Strokes and Months of Delayed Treatment
India's major cities have increasingly developed robotic surgery infrastructure and specialist teams. But access to highly specialised surgeons is not evenly distributed across the country. If remote robotic surgery can be safely scaled, a specialist in a major medical centre could operate on a patient in another city through a connected robotic system.
Dr. Anup Kumar said, “India is now at a defining moment in robotic surgery. The rapid rise in robotic procedures—from 8,912 nationally in 2021 to 44,857 in 2025—shows how quickly the technology is being adopted and how clinical expertise is expanding across the country. India is moving beyond being a technology adopter and is developing the experience, infrastructure and surgical capabilities required to become a global force in robotic surgery. If this momentum continues, India has the potential to emerge as a global leader by 2030 and compete with, and potentially surpass, established leaders such as the US. This is a proud moment for Indian healthcare and a significant opportunity to place India at the forefront of the next generation of surgery.”
Robotic telesurgery could also have other advantages besides bridging location gaps. The technology could support remote surgical training, tele-mentoring and collaboration between specialists when needed.
The SRS India 2026 conference also showcased a cross-border robotic telesurgery demonstration between India and China.
Dr. Vivek Bindal led the demonstration, with surgeons at Max Super Speciality Hospital, Vaishali, remotely operating a robotic console nearly 5,000 kilometres away in Chengdu, China during pre-clinical procedures.
Remote surgery requires more than a robotic surgical machine and a fast internet connection. The international consensus recommendations published in the World Journal of Surgery in 2026 address issues including connectivity, cybersecurity, surgeon training, credentialing, emergency preparedness and regulation.
There also needs to be a clear plan for what happens if the connection fails or the patient develops an unexpected complication during surgery.
For India, the technology could eventually help narrow the gap between where specialist surgeons are located and where patients live. But for that to happen, telesurgery will need strong infrastructure, trained teams, reliable connectivity and carefully defined safety protocols.
Credit: AI Generated Image
Fatty liver disease has traditionally been associated with obesity and alcohol consumption. However, in clinical practice, we are increasingly seeing fatty liver in individuals who may not appear overweight and who do not consume alcohol. This changing pattern reflects a larger problem: the close relationship between liver health, metabolic health, and lifestyle.
Non-alcoholic fatty liver disease (NAFLD), now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), occurs when excess fat accumulates in the liver in association with metabolic risk factors. A systematic review and meta-analysis of Indian studies estimated the pooled prevalence of NAFLD among adults at 38.6%, meaning that roughly one in three adults may be affected. The prevalence was approximately 28.1% in average-risk populations and increased to 52.8% among individuals with higher metabolic risk.
What is particularly important for Indians is that fatty liver cannot be identified simply by looking at body weight. South Asian populations can develop visceral or abdominal fat and metabolic abnormalities even at relatively lower body mass indices. A South Asian meta-analysis found that NAFLD affected approximately 26.9% of adults in the general population, while prevalence rose to 54.1% among people with metabolic diseases. Importantly, around 43.4% of people with NAFLD in the analysis were not obese.
Diabetes, hypertension, dyslipidaemia, central obesity and metabolic syndrome are therefore important warning signs. In my practice, I often emphasise that a normal-looking body does not necessarily mean a metabolically healthy body. Waist circumference, blood sugar, lipid profile, liver enzymes, and, when indicated, liver imaging provide a much more meaningful risk assessment.
The other misconception is that fatty liver is harmless. Simple steatosis may remain stable in many individuals, but some patients develop inflammation and progressive fibrosis, eventually leading to cirrhosis and liver cancer. A systematic review of hepatocellular carcinoma in India also found that the proportion of cases associated with NAFLD has been increasing, although viral hepatitis remains an important cause. ([PubMed][3])
There is also a broader gastroenterological concern. Digestive and liver health are closely connected with dietary patterns, physical activity, and metabolic health. Excessive intake of refined carbohydrates, sugary beverages, ultra-processed foods, and excessive calories, combined with inadequate physical activity, can contribute to metabolic dysfunction.
The good news is that lifestyle modification can make a substantial difference in fatty liver. Weight reduction, regular physical activity, improved dietary quality, adequate sleep, and better control of diabetes and cholesterol can help reduce liver fat and metabolic risk. Importantly, management should be individualised rather than based on crash diets or unregulated supplements.
Fatty liver should therefore be viewed not merely as an incidental finding on an ultrasound report, but as a metabolic warning signal. Early identification allows us to intervene before irreversible liver damage develops. For patients, the message is simple: taking care of the liver also means taking care of the heart, metabolism, and overall digestive health.
The statistics cited above are based on published systematic reviews/meta-analyses and IARC/WHO data; prevalence estimates vary depending on the population and diagnostic method.
Dr. Pradipta Kr. Sethy, Director Gastroenterology, Manipal Hospitals EM Bypass & Mukundupur
Credit: iStock
Endometriosis is a chronic disease affecting about 1 in 10 women worldwide. Diagnosis and treatment remain challenging, particularly for women with severe pain and other complications.
Now, US researchers have developed a targeted nanotherapy that showed promising results against endometriosis in early testing.
Scientists at Washington State University found that the treatment reduced endometriosis lesions, symptoms and pain sensitivity after a single dose in mice.
The findings were published in Advanced Healthcare Materials. Researchers hope to eventually test the treatment in humans.
Also read: Endometriosis Can Take Years To Diagnose But This AI Tool Can Identify Its Signs In 18 Milliseconds
The drug, niclosamide, was previously used to treat intestinal tapeworm infections in humans and is still used in animals.
Earlier research found that niclosamide could reduce endometriosis lesions and inflammation. However, it is not suitable for long-term use, limiting its potential as a treatment for a chronic condition.
To overcome this, researchers developed a nanotherapy that delivers niclosamide directly to cells associated with endometriosis.
“We found the disease-specific immune cell, and then we had a drug, but we couldn’t target the cell with the drug alone,” said Kanako Hayashi, professor at WSU’s School of Molecular Biosciences.
“So we used this nanocarrier that delivers the drug specifically to the disease site,” Hayashi said.
The team used a nanosized molecule called a dendrimer to bind with niclosamide and deliver it in a more soluble form.
In mice, a single injection reduced the size and number of lesions and lowered pain sensitivity.
“Although we still need to clear multiple phases, this study is telling us the efficacy is strong, and this nanocarrier is stable, so far, for two weeks—and we think we can go longer,” Hayashi said.
If the treatment remains stable for longer periods, researchers believe it could potentially be given less frequently. Hayashi said a monthly injection could be possible in the future, but this would depend on further testing.
READ: Endometriosis Taught Me To Always Listen To My Body, Says Model Padma Lakshmi
Not yet. The treatment has only been tested in mice and must undergo further safety and efficacy testing before human trials.
Researchers also do not yet know whether it would ultimately be given as an injection or IV infusion.
Endometriosis affects an estimated 190 million women worldwide. It occurs when tissue similar to the lining of the uterus grows outside the uterus.
It can cause severe pelvic pain, painful periods, pain during sex and infertility. Symptoms are sometimes dismissed as a “bad period,” contributing to delays in diagnosis.
There is currently no cure, although treatments can help manage symptoms.
Treatment depends on symptoms, disease severity and fertility goals.
Hormonal medicines can help control pain and disease activity but may cause side effects and can affect fertility while being used.
Painkillers, including non-steroidal anti-inflammatory drugs, may help manage discomfort.
Laparoscopic surgery can remove lesions and endometriotic cysts and may help restore pelvic anatomy. It can also improve fertility in some women, although the disease can recur.
Lifestyle measures such as regular exercise, stress management and dietary changes may also support symptom management.
© $2026 Times Horizon Private Limited